Categories: News

Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022

SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the ISN World Congress of Nephrology 2022 from February 24 – 27, 2022.

The following abstracts will be presented as poster presentations at the ISN World Congress of Nephrology 2022:

Atrasentan      
Abstract WCN22-0484     A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)
Author:     Hiddo J. L. Heerspink, PhD, PharmD, University Medical Center Groningen, Groningen, Netherlands
       
Abstract WCN22-0480     Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
Author:     Anjay Rastogi, MD, PhD, UCLA David Geffen School of Medicine, Los Angeles, CA
       
BION-1301      
Abstract WCN22-0485      Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Phase 1/2 Trial
Author:     Jonathan Barratt, MChB, PhD, FRCP, University of Leicester, Leicester, UK
       
Abstract WCN22-0483     ADU-CL-19: A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
Author:     Jonathan Barratt, MChB, PhD, FRCP, University of Leicester, Leicester, UK
       
For more information on these and other abstracts, please visit the ISN World Congress of Nephrology 2022 website.


About Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

CONTACT: Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
media@chinooktx.com 

Staff

Recent Posts

Redefining the Standard of Care: Introducing the Aulisa® Monitor Camera for Advanced Patient Monitoring

PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…

10 hours ago

Defence Announces Closing of Securities for Debenture Financing

Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…

15 hours ago

NuGen Announces Canada-Wide Launch of InsuJet

3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…

16 hours ago

purelyIV Launches Mobile App for Seamless Wellness Management

The new app allows users to browse services, book IV therapy, manage appointments, purchase packages,…

16 hours ago